Adding Chemotherapy in Medulloblastoma Linked With Improved Survival

Video

A recent retrospective study found that adding chemotherapy to postoperative treatment of craniospinal radiation for adults with medulloblastoma improves survival.

A recent retrospective study found that adding chemotherapy to postoperative treatment of craniospinal radiation improves survival in adult medulloblastoma patients.

The study examined 751 patients from the National Cancer Data Base: 520 received both chemotherapy and radiation therapy following surgery, and 231 received only radiation therapy. Estimated overall survival at 5 years was 86.1% in patients who received chemotherapy compared with 71.6% in patients who received radiation alone. One of the study limitations was the lack of information on tumor mutation status.

In this video Benjamin Kann, MD, of the Yale Cancer Center and Smilow Cancer Hospital in New Haven, Connecticut, discusses the results.

Recent Videos
The act of asking for help is critical to finding mentors who can help one advance in the brain cancer field, according to Yoshie Umemura, MD.
Through multidisciplinary collaboration, Yoshie Umemura, MD, and colleagues were able to organize the Gliofocus trial in brain cancer relatively fast.
Yoshie Umemura, MD, discusses how multiple departments can positively impact a patient with brain cancer during their visit to a medical center.
Antibody-drug conjugates and small molecule inhibitors may show utility in the neuro-oncology field, according to Nader Sanai, MD.
The phase 3 Gliofocus trial aims to meaningfully improve survival and quality of life with niraparib among patients with newly diagnosed glioblastoma.
Findings from a proof-of-concept study show a potential survival benefit with niraparib/radiotherapy in patients with newly diagnosed glioblastoma.
ZAP-X may provide submillimeter accuracy when administering radiation to patients with brain tumors.